NASDAQ: BJDX - Bluejay Diagnostics, Inc.

Rentabilité sur six mois: +2 150%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Bluejay Diagnostics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis.

plus de détails
In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2021-11-10
ISIN US0956331039
Industry Health Care Equipment & Supplies
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.bluejaydx.com
Цена ао 3.73
Changement de prix par jour: 0% (2.34)
Changement de prix par semaine: -20.68% (2.95)
Changement de prix par mois: -42.12% (4.0429)
Changement de prix sur 3 mois: -30.36% (3.36)
Changement de prix sur six mois: +2 150% (0.104)
Changement de prix par an: +324.68% (0.551)
Evolution du prix sur 3 ans: +108.93% (1.12)
Evolution des prix depuis le début de l'année: -39.06% (3.84)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 647.73 1
P/BV 0.1559 10
P/E 0 0
EV/EBITDA 0.1555 10
Total: 5.13

Efficacité

Nom Signification Grade
ROA, % -133.92 0
ROE, % -178.98 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0233 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 511.53 10
Rentabilité EPS, % 2277.6 10
Total: 8
Plus de détails

Établissements Volume Partager, %
Sabby Management, LLC 149926 5.58
Armistice Capital, LLC 24230 0.9
Citadel Advisors Llc 22077 0.82
Tower Research Capital LLC (TRC) 3252 0.12
JP Morgan Chase & Company 61 0
Osaic Holdings Inc 25 0
Wells Fargo & Company 6 0



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Indranil Dey Principal Financial, Accounting & Executive Officer, President, CEO and Director 413.16k 1963 (62 année)
Dr. Jason Cook Chief Technology Officer 278.42k 1982 (43 année)
Mr. Les DeLuca Vice President of Operations N/A
Mr. Kevin Vance Chief Commercial Officer N/A 1958 (67 années)
Mark W. Feinberg Chief Medical Advisor N/A
Dr. Mark W. Feinberg M.D. Chief Medical Advisor N/A

Adresse: United States, Acton. MA, 360 Massachusetts Avenue - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.bluejaydx.com